Kornimate/medical-research-clean huggingface dataset:
farming and movement evaluation study (fame)

Conditions: Parkinson's Disease; Movement Disorders

Summary: the long term goal of this research is to elucidate the cause(s) of parkinson's disease, with a focus on environmental determinants. we propose to investigate the relationship between parkinson's disease and exposure to pesticides and other factors by conducting a nested case-control study in the agricultural health study.

the long term goal of this research is to elucidate the cause(s) of parkinson's disease, with a focus on environmental determinants. we propose to investigate the relationship between parkinson's disease and exposure to pesticides and other factors by conducting a nested case-control study in the agricultural health study. the agricultural health study is a cohort study of 52,000 licensed pesticide applicators and 32,000 of their spouses, conducted in north carolina and iowa. it is a joint effort of the national cancer institute, the national institute of environmental health sciences, and the us environmental protection agency. the studies proposed here take full advantage of the agricultural health study. we believe that this work could provide a critical and dramatic next step in furthering our knowledge of environmental determinants of pd, and thereby take us closer to our goal of finding its cause(s)

Eligibility criteria:
inclusion criteria: * subjects will be recruited from members of the agricultural health study cohort.

Keywords: parkinson's disease movement disorders epidemiological study
vancomycin monitoring: is auc monitoring appropriate for more than just serious mrsa infections?

Conditions: MRSA

Summary: vancomycin, a glycopeptide antibiotic, is commonly prescribed as initial therapy for hospitalized patients due to its broad gram-positive coverage. vancomycin is used for the treatment and prevention of a variety of bacterial infections ranging from streptococcal to methicillin-resistant staphylococcus aureus (mrsa) infections.1 notable adverse effects of intravenous vancomycin include nephrotoxicity, ototoxicity and hypersensitivity reactions. given its pharmacokinetic profile, therapeutic drug monitoring is essential in determining the therapeutic efficacy of vancomycin as well as for avoiding nephrotoxicity.

vancomycin, a glycopeptide antibiotic, is commonly prescribed as initial therapy for hospitalized patients due to its broad gram-positive coverage. vancomycin is used for the treatment and prevention of a variety of bacterial infections ranging from streptococcal to methicillin-resistant staphylococcus aureus (mrsa) infections.1 notable adverse effects of intravenous vancomycin include nephrotoxicity, ototoxicity and hypersensitivity reactions. given its pharmacokinetic profile, therapeutic drug monitoring is essential in determining the therapeutic efficacy of vancomycin as well as for avoiding nephrotoxicity. the 2020 guidelines continue to enforce auc/mic as the preferred pk/pd parameter, but now recommend utilizing vancomycin peak and trough concentrations to target an auc/mic of 400-600 mg\*h/l for serious mrsa infections. although this auc goal is not new, the 2009 consensus guidelines previously recommended trough only monitoring as a simplistic surrogate marker for attaining this auc goal. furthermore, the most accurate way of calculating auc requires obtaining two steady state vancomycin serum concentrations over one dosing period. in this way, auc guided monitoring requires more pharmacist and nursing time, the use of more hospital resources and additional cost to the patient. as was true of the 2009 guidelines, the 2020 guidelines also leave certain questions unanswered. the paucity and conflicting data of vancomycin monitoring in patients with non-serious mrsa infections (skin and soft tissue infections, urinary tract infections, etc.), methicillin-sensitive staphylococcus aureus (mssa) infections and non-staphylococcal pathogen infections has left no guidance on the ideal vancomycin pk/pd targets in these patient populations. a literature search of auc/mic monitoring in patients with streptococcal and enterococcal infections yielded very few studies in patients with enterococcal infections and no studies in patients with streptococcal infections.

Eligibility criteria:
inclusion criteria: * patients hospitalized from june 2020- january 2021. * 18 years and older * at least 1 vancomycin trough concentration drawn at steady state * organism with an mic of 2 mg/l, if vancomycin was continued and in whom a steady state trough concentration was obtained exclusion criteria: * patients with end stage renal disease (on hemodialysis or peritoneal dialysis) or on continuous renal replacement therapy
fluticasone furoate treatment of daytime somnolence and cognitive performance in seasonal allergic rhinitis

Conditions: Seasonal Allergic Rhinitis

Summary: the hypothesis is that treating hay fever patients who had daytime sleepiness and slowed thinking because of the hay fever will improve when treated with an effective anti-hay fever medication, an intranasal steroid, that is will have less daytime sleepiness and demonstrate better thinking.

in this study of patients with seasonal allergic rhinitis we will monitor daytime sleepiness as measured by validated daytime sleep score (eppworth daytime sleepiness scale) and cognitive performance weekly as measured by a validated test of cognitive performance (tova). the treatment group with intervention of fluticasone furoate nasal spray 110 mcg two sprays in each nostril once daily will be compared to a placebo treated group of similar subjects with seasonal allergic rhinitis.

Eligibility criteria:
inclusion criteria: * symptomatic seasonal allergic rhinitis symptoms for at least 2 years at the time of study in the season of the study. * allergy skin tests positive for the airborne allergens present at the study time within the past 12 months. * a score of 2 or more on the nrqlq of the rhinitis quality of life questionnaire. * active allergic rhinitis on 4 of 7 days during run-in week, and evidence on sleep scales of drowsiness on 3 of 7 days. * ability to read, understand and give informed consent. * ability to understand and carry out responsibilities of the study exclusion criteria: * any chronic disease or other acute disease, which could influence central nervous system. * the use of any medication, which could affect central nervous system function. * unwillingness to participate in the study. * inability to understand testing procedures or use of medication. * hypersensitivity to fluticasone or vehicle of nasal sprays. * any sleep disorders including obstructive sleep apnea.

Keywords: hay fever daytime somnolence cognition
study of subcutaneous risankizumab injection to assess change in palmoplantar pustulosis area and severity index [pppasi] in adult japanese participants with palmoplantar pustulosis

Conditions: Palmoplantar Pustulosis (PPP)

Summary: palmoplantar pustulosis is a chronic inflammatory skin disease that causes repeated on and off symptoms like erythema (reddening, irritation), vesicle (swelling, cyst), pustules, scale, and crusts in palms and soles. this study evaluates how well risankizumab works compared to placebo (no medicine) to treat palmoplantar pustulosis. study will assess change in palmoplantar pustulosis area and severity index \[pppasi\]. risankizumab is an investigational drug being developed for the treatment of palmoplantar pustulosis. this study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given study drug and who will receive placebo (no medicine). participants are randomly put into 1 of 2 groups, called treatment arms to receive risankizumab or placebo in period a. in period b, each group receives both risankizumab and placebo at different time intervals. around 116 adult participants with palmoplantar pustulosis will be enrolled in approximately 39 sites across japan. participants will receive subcutaneous (sc) injections of risankizumab or placebo at week 0 and week 4 (period a). beginning week 16 (period b), both the groups will receive risankizumab and placebo at different intervals. total treatment duration is 56 weeks. there may be a higher burden for participants in this trial compared to their standard of care. participants will attend regular visits during the course of the study at a hospital or clinic. the effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.


Eligibility criteria:
inclusion criteria: * stable moderate to severe palmoplantar pustulosis (ppp) with a palmoplantar pustulosis area and severity index (pppasi) total score of \>= 12 at the screening and baseline visits. * moderate or severe pustules/vesicles on at least one palm or sole (\>= 2 pppasi severity score) at the screening and baseline visits. * experienced inadequate response (or intolerant) to treatment with topical corticosteroids and/or vitamin d3 derivative preparations and/or phototherapy and/or systemic etretinate. exclusion criteria: - history of active skin disease other than ppp which could interfere with the assessment of ppp.

Keywords: palmoplantar pustulosis (ppp) risankizumab skyrizi
early antibiotics after aspiration in icu patients

Conditions: Aspiration; Aspiration Pneumonia

Summary: the purpose of this study is to evaluate the use of early antibiotics in icu patients who appear to have aspirated, to help determine whether this improves outcomes by reducing the later incidence of pneumonia and other negative consequences.

icu patients with signs of aspiration on imaging and a clinical history supportive of aspiration, but with no clear signs of infectious pneumonia, will be randomized to receive either 5 days of empiric antibiotics or supportive care only. they will be followed for 30 days with a primary outcome of icu length-of-stay and various secondary outcomes including mortality, ventilator days, and antibiotic days.

Eligibility criteria:
inclusion criteria: * admitted to the icu within the last 24 hours, or with a witnessed aspiration event in the last 24 hours while in the icu * radiographic findings on chest x-ray or ct deemed by the treating icu team to be consistent with aspiration (e.g. dependent infiltrates or intraluminal airway debris) * clinical history consistent with possible aspiration (e.g. cardiac arrest, found unconscious, or with a witnessed aspiration event). exclusion criteria: * already received 3 or more doses of any antibiotic since hospital presentation, unless the last dose was greater than 1 week before enrollment * requires antibiotic therapy for the treatment of other infections * patient "comfort measures only" at time of screening * currently participating in other trials using investigational drugs or interventions * currently pregnant * currently a prisoner * the consenting party (patient or their legally authorized representative) is unable to understand or read english at a fifth-grade level. * 2 or more of the following are present at the time of screening: * white blood cell count: ≥ 11.0 * temperature ≥ 38.0c (100.4f) * purulent secretions * s/f (pulse oximetry saturation to fio2) ratio ≤ 215

Keywords: ventilator associated pneumonia
association of snowfall and myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: changes in the ambient temperature (esp. warm to cold) as well as exercise are triggers for vasospasms and plaque rupture. weather data (temperature, precipitation in general as well as snowfall and changes in atmospheric pressure) will be correlated with the incidence of myocardial infarctions.

besides classical cardiovascular risk factors such as smoking, obesity, elevated cholesterol levels and diabetes there are also acute factors potentially triggering acute coronary events. the impact of air temperature (changes) or humidity are of potential relevance. in addition, exercise and the associated increase in oxygen demand of the myocardium and blood pressure is another trigger for plaque rupture and the acute onset of myocardial infarction. male patients as well as patients with previous coronary heart disease or little regular exercise are at increased risk. possible additional mechanisms of exercise induced myocardial infarction are vasospasm and changes in blood clotting. changes in the ambient temperature (warm to cold) can also induce vasospasm which might result in reduced perfusion and plaque rupture. it seems that male patients are more involved than female patients. taking the exercise and the ambient temperature changes into consideration, heavy snowfall with consecutive snow shoveling is an augmented risk for acute myocardial infarction. the rationale of the study is to test if the above mentioned constellation of environmental factors as well as potential increased exercise have a significant and independent impact on the incidence of myocardial infarctions

Eligibility criteria:
inclusion criteria: * myocardial infarction being confirmed or treated in the cathlab exclusion criteria: * none
effects of exercise on sleep quality in patients with obstructive sleep apnea syndrome

Conditions: Osa Syndrome

Summary: the investigators aim in this study is to investigate the effects of aerobic and oropharyngeal exercises on sleep quality in patients with obstructive sleep apnea syndrome (osas).

the study will be conducted in a randomized controlled manner. participants will be divided into groups of 3 equal numbers using the simple randomization method. the control group will not be given exercise. the first intervention group will be given 10-15 minutes of oropharyngeal exercises. in addition to oropharyngeal exercises, the second intervention group will be given 50 minutes of moderate-intensity aerobic exercise at least 3 days a week. both intervention groups will apply the given exercise program for 8 weeks. all participants will be evaluated 3 times in total, at the beginning of the treatment, at the 4th week and at the 8th week. epworth sleepiness scale, pittsburgh sleep quality questionnaire, fatigue severity scale, berlin questionnaire, 6-minute walk test, modified medical research council (mmrc) dyspnea scale, functional results of sleep scale (fosq) tests will be applied to the participants. pre- and post-intervention data were statistically analyzed and compared.

Eligibility criteria:
inclusion criteria: * people who want to participate in the study voluntarily * people who do not regularly engage in physical activity * persons diagnosed with osas in the neurology outpatient clinic * people between the ages of 18-57 * apnea hypopnea index 15-30 exclusion criteria: * chronic obstructive pulmonary disease, presence of lung disease that may cause respiratory failure * -severe cardiac disease, congestive heart failure, detection of ejection fraction in echocardiography, uncontrollable cardiac ischemia * history of previous cerebrovascular disease * neuromuscular disease * presence of periodic leg movements * serious medical illness or planned surgical intervention * psychiatric illness, substance abuse

Keywords: osas quality of life sleep
study to evaluate the efficacy and safety of amg 714 in adult patients with type ii refractory celiac disease

Conditions: Type II Refractory Celiac Disease (RCD-II); In-situ Small Bowel T-cell Lymphoma

Summary: protocol celim-rcd-002 is designed to evaluate the efficacy and safety of amg 714 for the treatment of adult patients with type ii refractory celiac disease (rcd-ii), an in-situ small bowel t-cell lymphoma.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of refractory celiac disease type ii (rcd-ii) * greater than 20% aberrant intraepithelial lymphocytes (iel) as assessed by flow cytometry * on a gluten-free diet for at least 6 months * avoid pregnancy exclusion criteria: * enteropathy-associated t cell lymphoma (eatl) * infections * immune suppression * clinically significant co-morbidities
low dose rapamycin in me/cfs, long-covid, and other infection associated chronic conditions

Conditions: Myalgic Encephalomyelitis; Long-COVID

Summary: the goal of this observational study is to assess the clinical response and the effect of autophagy function in patients before, during and throughout oral low dose sirolimus (rapamycin) therapy. the main questions this study aims to answer are: * does rapamycin reduce the overall symptom burden in this patient population and does it improve the quality of life? * does rapamycin change mtor driven autophagy deficits observed in a subset of patients? participants will be asked to complete a series of questionnaires and quality of life instruments before starting rapamycin therapy prescribed by their physician and throughout their course of treatment. study blood samples will be collected before starting therapy and throughout the course of treatment to assess serological markers of autophagy function.


Eligibility criteria:
inclusion criteria: * diagnosis of me/cfs that meets the institute of medicine (iom) criteria * diagnosis of long-covid (pasc clinical criteria) exclusion criteria: * no diagnosis of me/cfs or long-covid

Keywords: me/cfs long-covid infection associated chronic conditions
creation of a clinical database on primary nervous system tumors

Conditions: Nervous System Tumor

Summary: the creation of a clinical database including data for all pcnst patients is of high interest. this database will allow us to develop clinical studies on: * the clinical, radiological and biological presentation of tumors, the impact of oncological treatments and the evaluation of survival for the different subtypes of primary central nervous system tumors (pcnst). this is particularly important for rare histological subtypes of pcnst for which the current knowledge is scarce; * clinical, radiological and biological factors predictive of tumor response to treatments; * prognostic factors.

primary central nervous system tumors (pcnst) correspond to all primitive tumors involving central nervous system structures, meninges and the origin of the cranial and paraspinal nerves. they have a malignant, benign, or borderline evolution. tpsnc represent a heterogeneous group of tumors, with more than 140 subtypes described in the who classification. the causes, prognostic factors, and therapeutic management differ according to the histological subtype. the incidence of all of tpsncs ranges from 17.6 to 22.0/105 in north american and european studies. however, because of the high number of different histological subtypes, most of them must be considered as rare tumors. moreover, they represent a major public health problem due to high morbidity \[8\] and mortality. in this context, the creation of a clinical database including data for all pcnst patients is of high interest. this database will allow us to develop clinical studies on: * the clinical, radiological and biological presentation of tumors, the impact of oncological treatments and the evaluation of survival for the different subtypes of pcnst. this is particularly important for rare histological subtypes of pcnst for which the current knowledge is scarce; * clinical, radiological and biological factors predictive of tumor response to treatments; * prognostic factors. the database will also allow us to develop or participate in multicentric clinical studies, at the national or international level, as well as to facilitate the identification of patients for inclusion in translational studies

Eligibility criteria:
inclusion criteria: * adult patient aged ≥ 18, no age limit; * diagnosis of primary central nervous system tumors ; * patient treated at the montpellier cancer institute, whatever the treatment received (systemic treatment, radiotherapy or exclusive supportive care); * for the retrospective part of the study, patient first treated at the montpellier cancer institute between january 1rst, 2004 and the beginning of the prospective part; * patient information for the retrospective (patient still alive at the beginning of the study) and prospective study. exclusion criteria: * secondary lesions of the central nervous system; * patient not affiliated to a social protection scheme; * subject under tutelage, curatorship or safeguard of justice.

Keywords: primary central nervous system tumors clinical database
a clinical study on the efficacy and safety of the treatment of hyperplasia of mammary glands with xiaoru sanjie capsule

Conditions: Fibrocystic Disease of Breast

Summary: the purpose of this study is to evaluate the efficacy and safety of xiaoru sanjie capsule in the treatment of cyclomastopathy.

this is a multicenter, randomized, open and parallel controlled clinical study.

Eligibility criteria:
inclusion criteria: * 18-65 years old female patients with cyclomastopathy who signed a written informed consent. * the subjects voluntarily entered the clinical observation whom are hospitalized patients or outpatients with good compliance. * they have specific symptoms, such as distending pain of the breast, stabbing pain, dull pain and radiating pain. * they have specific physical sign, for example, we can touch block gland, granular, nodular or cord like glands and etc.. * breast ultrasound or molybdenum target show i-iii class by breast imaging reporting and data system. exclusion criteria: * women who are pregnant or lactating, and who has the history of periarthritis of shoulder. * excluding breast fibrocellular tumor, breast cancer and other breast diseases. * patients with poor self coordination, mentally retarded patients, or have cardiovascular and cerebrovascular disease, severe organic disease, as well as the hematopoietic system disease or mental illness. * be judged as over middle degree depression by the hamilton's depression scale. * allergic constitution patients, and people who are allergic to a variety of drugs. * any medical history which may interfere with the test results or increase the risk of patients according to the investigators. * patients who have received treatment of other diseases, and those treatment methods and targets may have an impact on the indicators of this study.

Keywords: multicenter randomized open parallel controlled
distant management of crohn's disease by smartphones is feasible and effective additionally it reduces the costs

Conditions: Crohn Disease

Summary: evaluation of the feasibility, acceptability, patient satisfaction and economic benefits of smartphone video-based telehealth in the management of crohn's disease patients

patients were examined by two gastroenterologists (hy, aed) either at a video conference based visit or face to face visit in outpatients clinics. we used the whatsapp business application.the online visit notion was the same as traditional face-to-face visit except physical examination.

Eligibility criteria:
inclusion criteria: * the study group included patients with documented crohn's disease, based on clinical, endoscopic, and histologic findings * patient between 18-80 years old * participants who have been receiving treatment for more than six months exclusion criteria: * patients were excluded from the study if they had no internet connection * unable to use smartphones because of blindness, deafness, or mental disorders